Immunomodulation by multipotent mesenchymal stromal cells

被引:41
作者
Gotherstrom, Cecilia
机构
[1] Univ Hosp, Div Clin Immunol, S-14186 Huddinge, Sweden
[2] Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Immunol, Huddinge, Sweden
关键词
multipotent mesenchymal stromal cells; mesenchymal stem cells; cellular therapy; immunomodulation; immunosuppression; graft-versus-host disease;
D O I
10.1097/01.tp.0000269200.67707.c8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multipotent mesenchymal stromal cells (MSC) are currently under intense investigation to determine their role in cellular therapy. They are a rare subset of cells, but are easy to isolate and possess an extensive proliferative potential. MSC differentiate into cell types of mesenchymal and nonmesenchymal lineages, providing a promising tool for tissue repair. Studies in vitro have shown that they do not induce an immune response and inhibit cells of the immune system that are involved in alloantigen recognition and elimination. In animal models, MSC appear to have anti-inflammatory effects, which has also been observed in patients suffering from acute graft-versus-host disease. The unique properties of MSC suggest emerging roles for them in cell therapy and in the treatment of immunomediated diseases.
引用
收藏
页码:S35 / S37
页数:3
相关论文
共 26 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice [J].
Angelopoulou, M ;
Novelli, E ;
Grove, JE ;
Rinder, HM ;
Civin, C ;
Cheng, LZ ;
Krause, DS .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (05) :413-420
[3]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[4]  
Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
[5]  
2-F
[6]  
CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429
[7]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[8]   Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium [J].
Grinnemo, KH ;
Månsson, A ;
Dellgren, G ;
Klingberg, D ;
Wardell, E ;
Drvota, V ;
Tammik, C ;
Holgersson, J ;
Ringdén, O ;
Sylvén, C ;
Le Blanc, K .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (05) :1293-1300
[9]   Clarification of the nomenclature for MSC: The international society for cellular therapy position statement [J].
Horwitz, EM ;
Le Blanc, K ;
Dominici, M ;
Mueller, I ;
Slaper-Cortenbach, I ;
Marini, FC ;
Deans, RJ ;
Krause, DS ;
Keating, A .
CYTOTHERAPY, 2005, 7 (05) :393-395
[10]   T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression [J].
Klyushnenkova, E ;
Mosca, JD ;
Zernetkina, V ;
Majumdar, MK ;
Beggs, KJ ;
Simonetti, DW ;
Deans, RJ ;
McIntosh, KR .
JOURNAL OF BIOMEDICAL SCIENCE, 2005, 12 (01) :47-57